{"id":457951,"date":"2021-03-15T15:48:15","date_gmt":"2021-03-15T19:48:15","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=457951"},"modified":"2021-03-15T15:48:15","modified_gmt":"2021-03-15T19:48:15","slug":"investigation-alert-kessler-topaz-meltzer-check-llp-is-investigating-securities-fraud-claims-on-behalf-cytodyn-inc-investors","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-alert-kessler-topaz-meltzer-check-llp-is-investigating-securities-fraud-claims-on-behalf-cytodyn-inc-investors\/","title":{"rendered":"INVESTIGATION ALERT:  Kessler Topaz Meltzer &amp; Check, LLP is Investigating Securities Fraud Claims on Behalf CytoDyn Inc. Investors"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">RADNOR, Pa.<\/span>, <span class=\"xn-chron\">March 15, 2021<\/span> \/PRNewswire\/ &#8212;\u00a0The law firm of Kessler Topaz Meltzer &amp; Check, LLP is currently investigating potential violations of the federal securities laws on behalf of shareholders of CytoDyn Inc. (&#8220;CytoDyn&#8221;) (OTCMKTS: CYDY).\u00a0 <\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/277422\/ktmc_Logo.html\" target=\"_blank\" rel=\"nofollow noopener noreferrer\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/277422\/ktmc_Logo.jpg\" title=\"KTMC (PRNewsFoto\/Kessler Topaz Meltzer &amp; Check)\" alt=\"KTMC (PRNewsFoto\/Kessler Topaz Meltzer &amp; Check)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>CytoDyn is a late-stage biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 plays a critical role in the ability of HIV to enter and infect healthy T-cells.<\/p>\n<p>On <span class=\"xn-chron\">March 5, 2021<\/span>, CytoDyn issued a press release providing an update on its product &#8220;Vyrologix (leronlimab-PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications.&#8221; The press release stated, in part, that &#8220;the Phase 3 trial of leronlimab for the treatment of severe-to-critical patients with COVID-19 demonstrated continued safety, substantial improvement in the survival rate, and faster hospital discharge in critically ill COVID-19 patients.&#8221; <\/p>\n<p>Although the press release touted purportedly positive results, industry observers and analysts quickly characterized CytoDyn&#8217;s press release as misleading. For example, on <span class=\"xn-chron\">March 8, 2021<\/span>, <i>Seeking Alpha<\/i> published an article entitled &#8220;CytoDyn: Parsing Failure.&#8221; The <i>Seeking Alpha<\/i> article asserted that CytoDyn&#8217;s &#8220;leronlimab Phase 3 trial on COVID-19 severe-to-critical patients failed . . . \u00a0to meet both its primary endpoint and all secondary endpoints with any statistical significance&#8221; and described CytoDyn as having effectively &#8220;buried&#8221; the results in its press release. The article noted that &#8220;[a] normal biotech company would have stated this clearly, both in its PR titles and in their text bodies. Cytodyn, however, did something else.&#8221; <\/p>\n<p>Following this news CytoDyn&#8217;s common stock price fell <span class=\"xn-money\">$1.70<\/span> per share, or 41.98%, over the following two trading sessions, closing at <span class=\"xn-money\">$2.35<\/span> per share on <span class=\"xn-chron\">March 9, 2021<\/span>.<\/p>\n<p>\n        <b><br \/>\n          <i>If you are a CytoDyn investor and would like to learn more about our investigation, please contact Kessler Topaz Meltzer &amp; Check, LLP:\u00a0 <span class=\"xn-person\">James Maro, Esq.<\/span> (484) 270-1453 or <span class=\"xn-person\">Adrienne Bell, Esq.<\/span> (484) 270-1435; toll free at (844) 887-9500; via e-mail at <a href=\"mailto:info@ktmc.com\" rel=\"nofollow\">info@ktmc.com<\/a>; or please visit<\/i><br \/>\n        <\/b><br \/>\n        <b><br \/>\n          <i>the following link<\/i><br \/>\n        <\/b><br \/>\n        <b><br \/>\n          <i>to fill out our online form<\/i><br \/>\n        <\/b><br \/>\n        <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3097289-1&amp;h=2020918920&amp;u=https%3A%2F%2Fwww.ktmc.com%2Fcytodyn-inc-investigation%3Futm_source%3DPR%26utm_medium%3Dlink%26utm_campaign%3Dcytodyn&amp;a=https%3A%2F%2Fwww.ktmc.com%2Fcytodyn-inc-investigation%3Futm_source%3DPR%26utm_medium%3Dlink%26utm_campaign%3Dcytodyn\" rel=\"nofollow noopener noreferrer\">https:\/\/www.ktmc.com\/cytodyn-inc-investigation?utm_source=PR&amp;utm_medium=link&amp;utm_campaign=cytodyn<\/a><br \/>\n        <b>. <\/b>\n      <\/p>\n<p>Kessler Topaz Meltzer &amp; Check, LLP prosecutes class actions in state and federal courts throughout the country involving securities fraud, breaches of fiduciary duties and other violations of state and federal law. Kessler Topaz Meltzer &amp; Check, LLP is a driving force behind corporate governance reform, and has recovered billions of dollars on behalf of institutional and individual investors from <span class=\"xn-location\">the United States<\/span> and around the world. The firm represents investors, consumers and whistleblowers (private citizens who report fraudulent practices against the government and share in the recovery of government dollars).\u00a0For more information about Kessler Topaz Meltzer &amp; Check, LLP, please visit <u><a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3097289-1&amp;h=1206023357&amp;u=http%3A%2F%2Fwww.ktmc.com%2F&amp;a=www.ktmc.com\" rel=\"nofollow noopener noreferrer\">www.ktmc.com<\/a><\/u>.<\/p>\n<p>CONTACT:<br \/>Kessler Topaz Meltzer &amp; Check, LLP<br \/><span class=\"xn-person\">James Maro, Jr., Esq.<\/span><br \/><span class=\"xn-person\">Adrienne Bell, Esq.<\/span><br \/>280 King of Prussia Road<br \/><span class=\"xn-location\">Radnor, PA<\/span> 19087<br \/>(844) 887-9500<br \/><u><a target=\"_blank\" href=\"mailto:info@ktmc.com\" rel=\"nofollow noopener noreferrer\">info@ktmc.com<\/a><\/u><\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder2\"><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=DC09975&amp;sd=2021-03-15\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/investigation-alert--kessler-topaz-meltzer--check-llp-is-investigating-securities-fraud-claims-on-behalf-cytodyn-inc-investors-301247595.html\">http:\/\/www.prnewswire.com\/news-releases\/investigation-alert&#8211;kessler-topaz-meltzer&#8211;check-llp-is-investigating-securities-fraud-claims-on-behalf-cytodyn-inc-investors-301247595.html<\/a><\/p>\n<p>SOURCE  Kessler Topaz Meltzer &amp; Check, LLP<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=DC09975&amp;Transmission_Id=202103151545PR_NEWS_USPR_____DC09975&amp;DateId=20210315\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire RADNOR, Pa., March 15, 2021 \/PRNewswire\/ &#8212;\u00a0The law firm of Kessler Topaz Meltzer &amp; Check, LLP is currently investigating potential violations of the federal securities laws on behalf of shareholders of CytoDyn Inc. (&#8220;CytoDyn&#8221;) (OTCMKTS: CYDY).\u00a0 CytoDyn is a late-stage biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 plays a critical role in the ability of HIV to enter and infect healthy T-cells. On March 5, 2021, CytoDyn issued a press release providing an update on its product &#8220;Vyrologix (leronlimab-PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications.&#8221; The press release stated, in part, that &#8220;the Phase 3 trial of leronlimab &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-alert-kessler-topaz-meltzer-check-llp-is-investigating-securities-fraud-claims-on-behalf-cytodyn-inc-investors\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;INVESTIGATION ALERT:  Kessler Topaz Meltzer &amp; Check, LLP is Investigating Securities Fraud Claims on Behalf CytoDyn Inc. Investors&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-457951","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>INVESTIGATION ALERT: Kessler Topaz Meltzer &amp; Check, LLP is Investigating Securities Fraud Claims on Behalf CytoDyn Inc. Investors - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-alert-kessler-topaz-meltzer-check-llp-is-investigating-securities-fraud-claims-on-behalf-cytodyn-inc-investors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"INVESTIGATION ALERT: Kessler Topaz Meltzer &amp; Check, LLP is Investigating Securities Fraud Claims on Behalf CytoDyn Inc. Investors - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire RADNOR, Pa., March 15, 2021 \/PRNewswire\/ &#8212;\u00a0The law firm of Kessler Topaz Meltzer &amp; Check, LLP is currently investigating potential violations of the federal securities laws on behalf of shareholders of CytoDyn Inc. (&#8220;CytoDyn&#8221;) (OTCMKTS: CYDY).\u00a0 CytoDyn is a late-stage biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 plays a critical role in the ability of HIV to enter and infect healthy T-cells. On March 5, 2021, CytoDyn issued a press release providing an update on its product &#8220;Vyrologix (leronlimab-PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications.&#8221; The press release stated, in part, that &#8220;the Phase 3 trial of leronlimab &hellip; Continue reading &quot;INVESTIGATION ALERT: Kessler Topaz Meltzer &amp; Check, LLP is Investigating Securities Fraud Claims on Behalf CytoDyn Inc. Investors&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-alert-kessler-topaz-meltzer-check-llp-is-investigating-securities-fraud-claims-on-behalf-cytodyn-inc-investors\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-15T19:48:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/277422\/ktmc_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investigation-alert-kessler-topaz-meltzer-check-llp-is-investigating-securities-fraud-claims-on-behalf-cytodyn-inc-investors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investigation-alert-kessler-topaz-meltzer-check-llp-is-investigating-securities-fraud-claims-on-behalf-cytodyn-inc-investors\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"INVESTIGATION ALERT: Kessler Topaz Meltzer &amp; Check, LLP is Investigating Securities Fraud Claims on Behalf CytoDyn Inc. Investors\",\"datePublished\":\"2021-03-15T19:48:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investigation-alert-kessler-topaz-meltzer-check-llp-is-investigating-securities-fraud-claims-on-behalf-cytodyn-inc-investors\\\/\"},\"wordCount\":504,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investigation-alert-kessler-topaz-meltzer-check-llp-is-investigating-securities-fraud-claims-on-behalf-cytodyn-inc-investors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/277422\\\/ktmc_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investigation-alert-kessler-topaz-meltzer-check-llp-is-investigating-securities-fraud-claims-on-behalf-cytodyn-inc-investors\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investigation-alert-kessler-topaz-meltzer-check-llp-is-investigating-securities-fraud-claims-on-behalf-cytodyn-inc-investors\\\/\",\"name\":\"INVESTIGATION ALERT: Kessler Topaz Meltzer &amp; Check, LLP is Investigating Securities Fraud Claims on Behalf CytoDyn Inc. Investors - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investigation-alert-kessler-topaz-meltzer-check-llp-is-investigating-securities-fraud-claims-on-behalf-cytodyn-inc-investors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investigation-alert-kessler-topaz-meltzer-check-llp-is-investigating-securities-fraud-claims-on-behalf-cytodyn-inc-investors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/277422\\\/ktmc_Logo.jpg\",\"datePublished\":\"2021-03-15T19:48:15+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investigation-alert-kessler-topaz-meltzer-check-llp-is-investigating-securities-fraud-claims-on-behalf-cytodyn-inc-investors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investigation-alert-kessler-topaz-meltzer-check-llp-is-investigating-securities-fraud-claims-on-behalf-cytodyn-inc-investors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investigation-alert-kessler-topaz-meltzer-check-llp-is-investigating-securities-fraud-claims-on-behalf-cytodyn-inc-investors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/277422\\\/ktmc_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/277422\\\/ktmc_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investigation-alert-kessler-topaz-meltzer-check-llp-is-investigating-securities-fraud-claims-on-behalf-cytodyn-inc-investors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"INVESTIGATION ALERT: Kessler Topaz Meltzer &amp; Check, LLP is Investigating Securities Fraud Claims on Behalf CytoDyn Inc. Investors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"INVESTIGATION ALERT: Kessler Topaz Meltzer &amp; Check, LLP is Investigating Securities Fraud Claims on Behalf CytoDyn Inc. Investors - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-alert-kessler-topaz-meltzer-check-llp-is-investigating-securities-fraud-claims-on-behalf-cytodyn-inc-investors\/","og_locale":"en_US","og_type":"article","og_title":"INVESTIGATION ALERT: Kessler Topaz Meltzer &amp; Check, LLP is Investigating Securities Fraud Claims on Behalf CytoDyn Inc. Investors - Market Newsdesk","og_description":"PR Newswire RADNOR, Pa., March 15, 2021 \/PRNewswire\/ &#8212;\u00a0The law firm of Kessler Topaz Meltzer &amp; Check, LLP is currently investigating potential violations of the federal securities laws on behalf of shareholders of CytoDyn Inc. (&#8220;CytoDyn&#8221;) (OTCMKTS: CYDY).\u00a0 CytoDyn is a late-stage biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 plays a critical role in the ability of HIV to enter and infect healthy T-cells. On March 5, 2021, CytoDyn issued a press release providing an update on its product &#8220;Vyrologix (leronlimab-PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications.&#8221; The press release stated, in part, that &#8220;the Phase 3 trial of leronlimab &hellip; Continue reading \"INVESTIGATION ALERT: Kessler Topaz Meltzer &amp; Check, LLP is Investigating Securities Fraud Claims on Behalf CytoDyn Inc. Investors\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-alert-kessler-topaz-meltzer-check-llp-is-investigating-securities-fraud-claims-on-behalf-cytodyn-inc-investors\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-15T19:48:15+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/277422\/ktmc_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-alert-kessler-topaz-meltzer-check-llp-is-investigating-securities-fraud-claims-on-behalf-cytodyn-inc-investors\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-alert-kessler-topaz-meltzer-check-llp-is-investigating-securities-fraud-claims-on-behalf-cytodyn-inc-investors\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"INVESTIGATION ALERT: Kessler Topaz Meltzer &amp; Check, LLP is Investigating Securities Fraud Claims on Behalf CytoDyn Inc. Investors","datePublished":"2021-03-15T19:48:15+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-alert-kessler-topaz-meltzer-check-llp-is-investigating-securities-fraud-claims-on-behalf-cytodyn-inc-investors\/"},"wordCount":504,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-alert-kessler-topaz-meltzer-check-llp-is-investigating-securities-fraud-claims-on-behalf-cytodyn-inc-investors\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/277422\/ktmc_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-alert-kessler-topaz-meltzer-check-llp-is-investigating-securities-fraud-claims-on-behalf-cytodyn-inc-investors\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-alert-kessler-topaz-meltzer-check-llp-is-investigating-securities-fraud-claims-on-behalf-cytodyn-inc-investors\/","name":"INVESTIGATION ALERT: Kessler Topaz Meltzer &amp; Check, LLP is Investigating Securities Fraud Claims on Behalf CytoDyn Inc. Investors - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-alert-kessler-topaz-meltzer-check-llp-is-investigating-securities-fraud-claims-on-behalf-cytodyn-inc-investors\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-alert-kessler-topaz-meltzer-check-llp-is-investigating-securities-fraud-claims-on-behalf-cytodyn-inc-investors\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/277422\/ktmc_Logo.jpg","datePublished":"2021-03-15T19:48:15+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-alert-kessler-topaz-meltzer-check-llp-is-investigating-securities-fraud-claims-on-behalf-cytodyn-inc-investors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/investigation-alert-kessler-topaz-meltzer-check-llp-is-investigating-securities-fraud-claims-on-behalf-cytodyn-inc-investors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-alert-kessler-topaz-meltzer-check-llp-is-investigating-securities-fraud-claims-on-behalf-cytodyn-inc-investors\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/277422\/ktmc_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/277422\/ktmc_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investigation-alert-kessler-topaz-meltzer-check-llp-is-investigating-securities-fraud-claims-on-behalf-cytodyn-inc-investors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"INVESTIGATION ALERT: Kessler Topaz Meltzer &amp; Check, LLP is Investigating Securities Fraud Claims on Behalf CytoDyn Inc. Investors"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/457951","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=457951"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/457951\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=457951"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=457951"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=457951"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}